The purpose of this presentation is to outline regulatory decision-making for carcinogenic chemicals in
The first one, preferentially applied to industrial chemicals, is the categorization of chemicals into respective groups in a toxicity-ranking list: Class 1 Specified Chemical Substances, Class 2 Specified Chemical Substances, Designated Chemical Substances, and Safety-Certified Chemical Substances. It is necessary to mention that the term, SafetyCertified Chemical Substance, does not mean a safe substance in the scientific sense but merely indicates that a Chemical substance is approved to be free for production or importation. The Chemical Substance Control Law dictates the criteria for categorization based on experimental data and related information on chemicals such as the volume of manufacture or importation, biodegradation, bioaccumulation and toxicity ( Fig. 1 and Table 11) (5).
The second type of endpoint relates to establishment of acceptable doses, and tolerable levels or permissible limits for chemicals including decisions as to zero-tolerance. These are applied for various kinds of chemicals such as food additives, food contaminants, pesticides and work-place chemicals, and a series of testing guidelines and Good Laboratory Practice (GLP) standards to produce such data have been issued from the authorized agencies in Japan.
PROCEDURES OF REGUUTORY DECISION-MAKINO
Regulatory decisions for chemical substances are now made in Japan by analysis and integration of animal data and related scientific information on the substance according to the processes of risk assessment which includes 4 major steps: hazard identification, exposure assessment, dose-response assessment and risk characterization identification entails a qualitative evaluation ofdata concerning the potential of the chemical to produce a carcinogenic effect in man. Exposure assessment is the process of measuring or estimating real or hypothetical human exposure to the chemical of interest. Dose-response assessment is the evaluation of both hazard and exposure information to estimate the mathematical probability that the carcinogenic potential associated with the agent will be realized in the human population under defined conditions of exposure. In the final step, referred to as risk characterization, all relevant information from the first 3 steps is integrated to characterize the carcinogenic risk associated with expected human exposure to the chemical of interest.
Practically, the risk assessment of carcinogenic substances is meant to provide appropriate scientific resolution of the following issues: Whether the occurrence of cancer (in animals) is specifically attributable to genotoxicity of the compound or sequelae to some secondary influence exerted by the compound; and whether or not the modes, duration, and magnitude of anticipated exposure to the compound can be associated with significant increase of cancer incidence in man.
Regulatory decision-making is a complex matter with implications far beyond simple scientific judgment. It must include a decision to protect all interests. In other words, a multidisciplinary approach is required for regulatory decision-making. For that 
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UNCERTAINTIES M RISK ASSESSMENT
Regulatory decision-making on the safety of chemicals starts with a scientific procedure to assess or infer the risk level or risk profile based on existing information. The execution of any given risk assessment may be influenced by involvement of various uncertainties resulting from deficiencies or critical gaps in the necessary information. On such occasions, it is required to make assumptions or inference rules based on prevailing scientific thought, taking these uncertainties into account, so that the assessment can be completed (7). Therefore, the plausibility of these assumptions is regarded as a critical factor influencing the result of risk assessment. Thus, inappropriate assumptions may yield inappropriate assessment due to either over-estimation or under-estimation of risk.
PARTICIPATION OF PATHOLOGISTS
IN RISK ASSESSMENT
During the course of any given risk assessment, pathologists are assigned to various tasks. Involvement of pathologists occurs mostly during the steps of hazard identification which include establishing whether the lesions found in animals are primarily related to administration of the chemical, elucidating the pathological implication of biological nature of the lesions such as being reversible, irreversible, progressive, life-threatening or adverse to organ functions, and also determining, based on dose-effect data, the NOAEUNOEL or the mathematical probability of their occurrence under defined conditions of exposure. Involvement of uncertainties impacting on the process of risk assessment may arise from issues related to pathological implications or biological characteristics of the lesions. Liver foci represent a typical example.
CERTAINTIES vs UNCERTAINTIES WITH
RESPEC~ TO L n m FOCI Liver foci or altered hepatocellular foci are focal lesions of the liver easily detectable in paraffin sections as phenotypically altered cell populations of hepatocytes. Foci are identified in routine histological preparations or in histochemically stained sections. The occurrence of liver foci can also be quantitatively estimated by application of stereological techniques (1). Furthermore, it is generally accepted that liver foci are inert lesions in themselves, neither life-threatening nor adversely affecting liver function. Therefore, the results of risk assessment for a chemical capable of preferentially causing an increase in liver foci in rats is highly dependent upon the view of the regulators or regulatory scientists concerning the pathological significance of liver foci as precursor lesions for hepatocellular cancer or the value of liver foci as predictors for hepatocarcinogenicity of the chemical.
Current information on the biological significance of liver foci is still controversial and insufficient. Complete information is lacking on the reversibility or irreversibility of liver foci. Under certain experimental conditions, liver foci may disappear aAer cessation of treatment (1). Age-associated increase of spontaneously occurring liver foci has been noted in some rat strains (1) but this information should be confirmed and extended to additional strains commonly used for carcinogenicity testing.
There is some supporting evidence with regard to the progression of liver foci to malignancy. Carcinogenicity studies with potent hepatocarcinogens result in the occurrence of liver foci in association with the development of frank hepatocellular tumors. Occasionally, we can notice a tiny malignant cell focus in a benign liver nodule (8) suggestive of the development of malignant from benign neoplasms. In contrast is the observation that liver foci appear very frequently in aged Fischer 344 rats, but the spontaneous occurrence of hepatocellular tumors is very low in this rat strain (3).
Histologically or histochemically rat liver foci can be divided into various types, such as clear cell foci, acidophilic cell foci, basophilic cell foci, vacuolated cell foci, mixed cell foci. GGT-positive foci, GSTPpositive foci, or ATP-negative foci. In addition to these heterogeneous cytological or cytochemical markers, we can assume that there are at least 2 types of biologically different liver foci: liver foci with a potential of developing into malignancy and liver foci without that potential or with very little potential of developing into malignancy. Empiri- cally, basophilic cell foci have been singled out as being particularly relevant to hepatocarcinogenesis (3) while clear cell foci induced by carcinogens are partly reversible aAer withdrawal of the chemical (2). At present, we have no definite morphological criteria to identify the biological behavior of liver foci.
PRINCIPLE AND P R A~C E
OF REGULATORY
DECISION-MAKING ON ISSUES RELATED TO
LIVER FOCI It must be realized that under circumstances complicated by various uncertainties as mentioned above, regulators or regulatory scientists are dealing with issues related to occurrence of liver foci. In principle, their considerations in making decisions involve at least 2 steps. First, the occurrence of liver foci is taken into account as evidence suggesting that the chemical has a potential of enhancing, in some fashion, development of hepatocellular tumors. Second, information concerning the mode ofaction and potency of the chemical for causing liver foci as well as real or hypothetical exposure levels and durations of exposure to the chemical in humans are considered for evaluation of human risk.
In general, regulatory issues related to liver foci start with evaluation of 2-yr rat studies. Therefore, the first problem for regulators to decide or consider, on the basis of test data, is to which type of hepatocarcinogen the compound belongs: a strong complete carcinogen, a weak complete carcinogen, a promoter, or a pure initiator. Theoretically, this kind of categorization appears to be possible if sufficient data are available on the incidence and size of liver foci and incidence of frank hepatocellular tumors in treated and control groups (Table 111) . However, the occurrence of liver foci is highly influenced by various factors such as chemical exposure level, duration of exposure to the chemical, strain of test animals, and experimental conditions including composition of the diet. Furthermore, the data from routine carcinogenicity studies are limited to the incidence of liver foci and liver tumors in the control and treated groups (Table IV) . Therefore, it is difficult in practice to distinguish the effect of a weak complete carcinogen from that of a promoter based on routine test data. For example, in a case where the submitted data clearly show a significantly higher incidence of liver foci and frank hepatocellular in the treated versus the control groups, regulators may decide that the compound be classified as a complete hepatocarcinogen. The decision may be confinned by the results of long-term mouse studies and mutagenicity studies. In contrast, when the submitted data show that the occurrence of liver foci is significantly higher in the treated groups than in the control groups, but the incidence of liver tumors is almost comparable among the groups, the regulators have difficulty in classifying the compound as a weak complete carcinogen versus as a promoter. In such a case, regulators require, for reinforcement of their decision, additional information on the compound such as medium-term assay data for hepatocarcinogenic promotion or initiation activity obtained from any one of several rat liver focus models (1,4) . The results of long-term mouse studies and mutagenicity testings also help in these considerations.
FUTURE RESEARCH PROJECTS ON
RAT LIVER FOCI Rat liver foci can be easily identified in paraffin sections by routine histological or histochemical examination and even quantitative evaluation is now possible by proper application of stereological techniques. However, the pathological or biological characteristics of foci still remain unsettled and this hampers regulatory judgments regarding the hepatocarcinogenic potential of chemicals. From the viewpoint of regulators or regulatory scientists, therefore, future studies on liver foci should be directed more to aspects of biological significance. Projects may include: 1) typing of liver foci in relation to observed biological behavior and 2) establishment of criteridmethods to identify the type of foci relevant to development of hepatocellular tumors. At present, we have not been provided with any direct evidence indicating that the probability for transition from liver foci to malignancy is greater than that from normal hepatocytes to liver cancer. 
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